AAVantgarde closed a $141 million Series B led in part by Amgen Ventures to advance gene therapies for inherited retinal diseases. The Milan-based biotech will deploy capital toward programs targeting two forms of inherited blindness and to accelerate preclinical and IND-enabling work. Amgen’s participation signals continued big-pharma interest in ocular AAV platforms and de‑risking at the series‑B stage.